<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01//EN"
"http://www.w3.org/TR/html4/strict.dtd">
<!--[if lt IE 7 ]><html class="ie ie6" lang="en"> <![endif]-->
<!--[if IE 7 ]><html class="ie ie7" lang="en"> <![endif]-->
<!--[if IE 8 ]><html class="ie ie8" lang="en"> <![endif]-->
<!--[if (gte IE 9)|!(IE)]><!--><html lang="en"> <!--<![endif]-->
<head>
	<!-- CSS
  ================================================== -->
	<link rel="stylesheet" href="/resources/stylesheets/layout.css">
	<link rel="stylesheet" href="/resources/stylesheets/content.css">
	<link rel="stylesheet" href="/resources/stylesheets/print.css">
	<link rel="stylesheet" href="/resources/stylesheets/font-awesome.css">

	<!-- Basic Page Needs
  ================================================== -->
    <script src="/resources/libraries/jquery-1.8.3.min.js" type="text/javascript"></script>
    <script type="text/x-mathjax-config">
	MathJax.Hub.Config({
	  "HTML-CSS": { linebreaks: { automatic: true } },
	         SVG: { linebreaks: { automatic: true } }
	});
	</script>
    <script type="text/javascript" async src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
	<meta charset="utf-8">
	<title>Reproduction</title>
	<meta name="description" content="Course Notes for Reproduction">
	<meta name="author" content="Kevan Lu">
	<meta name="robots" content="noindex,nofollow"/>
	
	<!-- Mobile Specific Metas
  ================================================== -->
	<meta name="viewport" content="width=device-width, height=device-height, initial-scale=1.0, maximum-scale=1.0"/>

	<script>
	  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
	  (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
	  m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
	  })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

	  ga('create', 'UA-40381402-3', 'auto');
	  ga('send', 'pageview');
	</script>

	<!-- Favicons
	================================================== -->
	<link rel="shortcut icon" href="/references/favicon.png" type="image/png">

	<!-- iOS Icons
	================================================== -->
	<link href="/resources/images/icon-iphone.png" rel="apple-touch-icon"/>
	<link href="/resources/images/icon-ipad.png" rel="apple-touch-icon" sizes="76x76" />
	<link href="/resources/images/icon-iphone-retina.png" rel="apple-touch-icon" sizes="120x120"/>
	<link href="/resources/images/icon-ipad-retina.png" rel="apple-touch-icon" sizes="152x152" />
</head>
<body>
    <div id="home-overlay">
	<div class="index"><a href="http://www.schulichnotes.com"><i class="fa fa-stethoscope"></i> Schulich Notes</a></div>
	<div id="header-search-icon"><a id="header-search-button"><i class="fa fa-search"></i></a></div>
</div>
<div id="header-search-bar">
	<form class="search" action="http://www.schulichnotes.com/reproduction/search.html">
	<div><input type="text" value="Search Reproduction" onfocus="if(this.value==this.defaultValue)this.value='';" onblur="if(this.value=='')this.value=this.defaultValue;" name="q" id="tipue_search_input"></div>
	</form>
</div>
<div id="overlay"><h1><a style="border:none;" href="http://www.schulichnotes.com/reproduction">Reproduction</a></h1></div>
    <div class="sidebar-background"></div>
    <div class="sidebar">
        <!-- Displays a Search Bar-->
<div class="search-wrapper">
	<div class="index"><a href="http://www.schulichnotes.com"><i class="fa fa-stethoscope"></i> Schulich Notes</a></div>
	<form class="search" action="http://www.schulichnotes.com/reproduction/search.html">
	<div style="float: left;"><input type="text" value="Search Reproduction" onfocus="if(this.value==this.defaultValue)this.value='';" onblur="if(this.value=='')this.value=this.defaultValue;" name="q" id="tipue_search_input"></div>
	<div style="float: left;"><input type="button" id="tipue_search_button" onclick="this.form.submit();"></div>
	<div style="clear: left;"></div>
	</form>
</div>

        <div class="course-toc">
            <div class="course-index">
                <a href="http://www.schulichnotes.com/reproduction">Reproduction</a>
            </div>
            <nav>	
	<li class="week">Week 1</li>
	<ul>
		<li class="day">Monday, November 10</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/10/intro-reproduction.html">Introduction to Reproduction</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/10/embryology-female-reproductive-tract.html">Embryology of the Female Reproductive Tract</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/10/anatomy-female-reproductive-tract.html">Anatomy of the Female Reproductive Tract</a></li></ul>
		<li class="day">Tuesday, November 11</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/11/anatomy-perineum.html">Anatomy of the Perineum</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/11/functional-sexual-anatomy.html">Functional Sexual Anatomy</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/11/histology-pathology-female-male-reproductive-tract.html">Histology &amp; Pathology of Female &amp; Male Reproductive Tracts</a></li></ul>
		<li class="day">Wednesday, November 12</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/12/male-reproductive-physiology.html">Male Reproductive Physiology</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/12/female-reproductive-physiology.html">Female Reproductive Physiology</a></li></ul>
		<li class="day">Thursday, November 13</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/13/introduction-gynecological-clinical-exam.html">Introduction to the Gynecological Clinical Exam</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/13/hpo-axis-menstrual-cycle.html">The HPO Axis and the Menstrual Cycle</a></li></ul>
		<li class="day">Friday, November 14</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/14/pharmacology-contraception.html">Pharmacology of Contraception</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/14/female-pelvis-anatomy-lab.html">Female Pelvis Anatomy Lab</a></li></ul>
	</ul>
	<li class="week">Week 2</li>
	<ul>
		<li class="day">Monday, November 17</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/17/TBL-small-group-notes.html">TBL Small Group Notes</a></li></ul>
		<li class="day">Tuesday, November 18</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/18/understanding-promoting-reproductive-health-behaviours.html">Understanding &amp; Promoting Reproductive Health Behaviours</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/18/approach-amenorrhea.html">Approach to Amenorrhea</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/18/approach-abnormal-bleeding.html">Approach to Abnormal Bleeding</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/18/perineum-anatomy-lab.html">Perineum Anatomy Lab</a></li></ul>
		<li class="day">Wednesday, November 19</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/19/approach-vulva-vagina-stis.html">An Approach to the Vulva, Vagina, &amp; STIs</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/19/approach-acute-chronic-pelvic-pain.html">An Approach to Acute &amp; Chronic Pelvic Pain</a></li></ul>
		<li class="day">Thursday, November 20</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/20/pathology-abnormal-bleeding.html">Pathology of Abnormal Bleeding</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/20/pathology-pelvic-pain.html">Pathology of Pelvic Pain</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/20/chsg-adolescent-amenorrhea.html">Child Health Small Groups &ndash; Adolescent Amenorrhea</a></li></ul>
		<li class="day">Friday, November 21</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/21/clinical-anatomy-review.html">Clinical Anatomy Review</a></li></ul>
	</ul>
	<li class="week">Week 3</li>
	<ul>
		<li class="day">Monday, November 24</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/24/summary-gynecologic-cancer.html">Summary of Gynecologic Cancer</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/24/cervical-cancer-screening.html">Cervical Cancer Screening</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/24/clinical-exam-cervix.html">Clinical Exam of the Cervix</a></li></ul>
		<li class="day">Tuesday, November 25</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/25/issues-perimenopause-menopause.html">Issues of Perimenopause &amp; Menopause</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/25/pelvic-organ-prolapse.html">Pelvic Organ Prolapse</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/25/approach-pathology-post-menopausal-bleeding.html">Approach to &amp; Pathology of Post-Menopausal Bleeding</a></li></ul>
		<li class="day">Wednesday, November 26</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/26/approach-pelvic-mass.html">Approach to a Pelvic Mass</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/26/gynecologic-tract-imaging.html">Gynecologic Tract Imaging</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/26/family-physician-approach-breast-problems.html">A Family Physician's Approach to Common Breast Problems</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/26/pathology-pelvic-mass.html">Pathology of a Pelvic Mass</a></li></ul>
		<li class="day">Thursday, November 27</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/27/breast-anatomy-histology.html">Breast Anatomy &amp; Histology</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/27/clinical-examination-breast.html">Clinical Examination of the Breast</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/27/breast-pathology.html">Breast Pathology</a></li></ul>
		<li class="day">Friday, November 28</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/28/breast-imaging.html">Breast Imaging</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/28/surgical-management-breast-cancer.html">Surgical Management of Breast Cancer</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/28/medical-management-breast-cancer.html">Medical Management of Breast Cancer</a></li></ul>
	</ul>
	<li class="week">Week 4</li>
	<ul>
		<li class="day">Monday, December 1</li>
		<ul></ul>
		<li class="day">Tuesday, December 2</li>
		<ul></ul>
		<li class="day">Wednesday, December 3</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/12/03/approach-sexual-orientation.html">Approach to Sexual Orientation</a></li></ul>
		<li class="day">Thursday, December 4</li>
		<ul></ul>
		<li class="day">Friday, December 5</li>
		<ul></ul>
	</ul>
	<li class="week">Week 5</li>
	<ul>
		<li class="day">Tuesday, December 9</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/12/09/drug-exposure-pregnancy-lactation.html">Drug Exposure in Pregnancy and Lactation</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/12/09/embryology-anatomy-placenta.html">Embryology &amp; Anatomy of the Placenta</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/12/09/first-trimester-bleeding-il.html">First Trimester Bleeding IL</a></li></ul>
		<li class="day">Wednesday, December 10</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/12/10/physiology-pregnancy.html">Physiology of Pregnancy</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/12/10/prenatal-screening-diagnosis.html">Prenatal Screening and Diagnosis</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/12/10/fetal-ultrasound.html">Fetal Ultrasound</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/12/10/first-trimester-complications.html">First Trimester Complications</a></li></ul>
		<li class="day">Thursday, December 11</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/12/11/fetal-growth-health.html">Fetal Growth &amp; Health</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/12/11/hypertension-pregnancy.html">Hypertension in Pregnancy</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/12/11/premature-labour.html">Premature Labour</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/12/11/multiple-gestation.html">Multiple Gestation</a></li></ul>
		<li class="day">Friday, December 12</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/12/12/labour-birth.html">Labour & Birth</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/12/12/complicated-labour-c-section-vbac.html">Complicated Labour, Caesarian Section, VBAC</a></li></ul>
	</ul>
	<li class="week">Week 6</li>
	<ul>
		<li class="day">Monday, December 15</li>
		<ul></ul>
		<li class="day">Tuesday, December 16</li>
		<ul></ul>
		<li class="day">Wednesday, December 17</li>
		<ul></ul>
		<li class="day">Thursday, December 18</li>
		<ul></ul>
	</ul>
</nav>
        </div>
    </div>
    <div class="content-offset">
        <div class="content-background"></div>
        <div class="content">
            <div class="single post">
                <!-- Post Layout -->
                <div class="title"><h1>Issues of Perimenopause &amp; Menopause</h1></div>
                <info datetime="2014-11-25">
                    <span class="author"><a href="http://www.schulichnotes.com/about.html#kevanlu">Kevan Lu</a></span>
                    <span class="date">Tuesday, November 25, 2014</span>
                </info>
                <div class="body"><blockquote>
  <p>####<strong>Objective</strong>
- <em>Define perimenopause and menopause</em>.</p>
</blockquote>

<ul>
  <li><strong>Perimenopause</strong>: the 2-8 years preceding menopause and the first year after the final menstrual period.</li>
  <li><strong>Menopause</strong>: permanent cessation of menstruation resulting from loss of follicular activity, occurs <em>after 12 consecutive months of amenorrhea</em> for which there is no other pathological or physiological cause.
    <ul>
      <li>Once you’re in menopause, you’re forever in menopause; it’s not really a ‘pause’.</li>
    </ul>
  </li>
</ul>

<blockquote>
  <p>####<strong>Objective</strong>
- <em>Describe the physiology of the HPO axis during perimenopause and menopause.</em></p>
</blockquote>

<p>####<strong>Perimenopause</strong>
- During perimenopause, women will have fluctuating hormone levels, and their periods will come at irregular intervals.
- Symptoms of decreased estrogen levels will gradually increase in number and severity as menopause approaches.
- There’s also an <em>accelerated rate of follicular depletion</em>:
	- This isn’t because they run out of eggs; this is another common myth.
	- <em>You never run out of eggs</em>; it’s just that your ovaries stop responding to pituitary signals.
- In some months, perimenopausal women will have normal ovulation and hormone level; in other months, they will have anovulation and erratic hormones.
- <strong>What happens to hormone levels in perimenopause?</strong>
	<img class="right" src="/images/ws5thj_3.png" />
	- <em>Circulating progesterone falls</em> → since there are anovulatory cycles, and the corpus luteum produces progesterone, progesterone falls.
	- <em>Gradually increasing FSH levels</em> → since ovulation occurs less frequently, the pituitary sends out stronger signals to the ovary to ovulate; hence, the increased FSH.
	- <em>LH levels remain normal</em>
	- <em>Decreased levels of inhibin A and B</em>
		- Recall that inhibins inhibit FSH secretion.
		- Since you want to <i>increase</i> FSH to stimulate ovulation during perimenopause, it makes sense that inhibins would fall.
	- <em>Estrogen falls</em> → this is most marked in the 6 months prior to menopause.
	- <em>Testosterone:Estrogen Ratio rises</em>:
		- The ovary will continue to make testosterone and androstenedione, since LH levels remain the same, and LH stimulates Leydig cells to produce androgens.
		- Since estrogen falls, but the testosterone levels remain the same, women may often see some subtle signs of virilization at this point.
		- This can be seen below.</p>

<p><img src="/images/-90y6u5n.png" /></p>

<blockquote>
  <p>####<strong>Objective</strong>
- <em>Reasons why women present to healthcare system during menopause</em>.
- <em>Describe physiologic mechanisms that explain these conditions</em>.</p>
</blockquote>

<ul>
  <li><strong>Menstrual irregularities and changes</strong>.
    <ul>
      <li>These are due to the erratic hormone levels and irregular ovulation described above.</li>
    </ul>
  </li>
  <li><strong>Vasomotor symptoms</strong> → hot flushes, night sweats.
    <ul>
      <li><em>Vasomotor symptoms are the most frequent complaint, and the one most directly attributable to hormonal changes</em>.</li>
      <li><strong>Hot flushes</strong> → recurrent, transient episodes of flushing, sweating and <i>sensation</i> of heat (there’s no actual temperature change).
        <ul>
          <li>These hot flushes are often preceded by palpitations and anxiety, and are usually succeeded by chills.</li>
          <li>Risk factors and triggers for hot flushes include: obesity, cigarette smoking, alcohol, warm beverages, and warm ambient temperatures.</li>
        </ul>
      </li>
    </ul>
  </li>
  <li><strong>Mastalgia</strong>.
    <ul>
      <li>Breast tenderness experienced here is often cyclical.</li>
      <li>Physiologically, <em>breast tissue is stimulated by progesterone levels</em>; hence, pain is often worst in the luteal phase.</li>
      <li>This may be significant in early perimenopause, when hormone levels are fluctuating, and progesterone has yet to fall significantly.</li>
      <li>This improves in late perimenopause and postmenopause since progesterone levels fall, so there’s less breast stimulation. </li>
    </ul>
  </li>
  <li><strong>Poor sleep, fatigue, lack of energy</strong>.
    <ul>
      <li><em>Oftentimes, it’s due to vasomotor symptoms</em> like hot flushes and night sweats.</li>
      <li>However, there are many women who do have sleep disturbances that are independent to vasomotor symptoms. This is due to the fact that <em>there is also a change in the sleep pattern</em>.</li>
      <li>There’s an unknown mechanism, but estrogen receptors <i>are</i> found in the sleep regulatory centre in the CNS.</li>
      <li>May see a decrease in REM sleep.</li>
    </ul>
  </li>
  <li><strong>Urogenital symptoms</strong> → vaginal dryness, dyspareunia, urinary incontinence.
    <ul>
      <li>Women are often afraid to bring this up, but it’s almost a universal symptom.</li>
      <li>Recall that <em>estrogen receptors are present throughout the urogenital tract</em>, and are responsible for maintaining the thickness, elasticity, vascularization, and moistness of the UG tract.</li>
      <li>When estrogen levels fall, you lose all of this. Hence, you have loss of all of the above.</li>
      <li>The vulva loses collagen and adipose tissue; the vulva loses moisture; the prepuce of the clitoris atrophies; the vaginal surface thins, becomes less elastic, and more friable.</li>
      <li>Recurrent UTIs, vaginal infections increase.</li>
      <li>Stress/urge incontinence also increases.</li>
    </ul>
  </li>
  <li><strong>Sexual dysfunction</strong> → decreased libido.
    <ul>
      <li>Decreased libido is a significant complaint.</li>
      <li>It’s postulated that this is <em>due to decreased levels of testosterone</em>; even though the testosterone:estrogen ratio does rise throughout perimenopause and menopause, the absolute testosterone level does fall somewhat.</li>
      <li>Decreased libido may also be due to worsening health and activity; healthy and active women are hornier.</li>
      <li>Finally, there’s a <em>psychosomatic element to this</em> → complaints about this seem to vary depending on cultural and personal expectations.</li>
    </ul>
  </li>
  <li><strong>Mood swings, depression</strong>.
    <ul>
      <li>Women entering menopause report increases in depression and anxiety.</li>
      <li>Physiologically, this may be due to the fact that <em>estrogen upregulates the serotonergic system</em>. Indirectly, it has been shown that dysfunction in serotonin regulation can result in mood disorders.</li>
      <li>However, <em>current evidence does not support an association between estrogen levels and depression</em>. (evidence is very mixed)</li>
      <li>Depression may also be a result of all the other physiological changes described.</li>
    </ul>
  </li>
  <li><strong>Change in cognition</strong>.
    <ul>
      <li>Estrogen potentiates neuritic outgrowth, dendritic spine formation and synapse formation.</li>
      <li>The basal forebrain and hippocampus (which plays a role in memory) contain estrogen receptors. Hence, reduced estrogen may result in worsening memory.</li>
      <li>Estrogen has been shown to increase cerebral blood flow and modulate cerebral glucose utilization.</li>
      <li>In summary, <em>estrogen seems to have a neuroprotective role</em>.</li>
      <li>There’s limited data that suggests there may be a decreased risk of dementia is estrogen is given in early menopause. However, this is also controversial.</li>
    </ul>
  </li>
</ul>

<blockquote>
  <p>####<strong>Objective</strong>
- <em>Physiology of vasomotor symptoms and their management</em>.</p>
</blockquote>

<ul>
  <li>We’re not completely sure why this happens, however there are <em>2 theories</em>;
    <ol>
      <li>There are <em>low levels of estrogen</em> at the thermoregulatory centre of the hypothalamus.</li>
      <li>There’s a <em>decreased ability for estrogen to bind</em> to estrogen receptors at the thermoregulatory centre of the hypothalamus.</li>
    </ol>
  </li>
  <li>Whether it’s a decreased amount of estrogen, or decreased sensitivity, the end result is the same; <em>their thermo-neutral zone becomes more narrow.</em>
    <ul>
      <li>In other words, although their core body temperature remains the same, the zone at which they <i>feel</i> like they are at their correct temperature becomes more narrow.</li>
      <li>When they feel hot, this triggers a vasodilatory response to cool the body down, which is what results in the flushing and sweating.</li>
    </ul>
  </li>
</ul>

<blockquote>
  <p>####<strong>Objective</strong>
- <em>Describe treatment options for menopausal symptoms</em>.
- <em>List evidence for the menopausal guidelines</em>.</p>
</blockquote>

<p>####<strong>Lifestyle Modification</strong>
- <em>The best choice is lifestyle modification</em> (and all the obvious ones too):
	- Diet and exercise for weight maintenance.
	- Reducing core body temperature.
	- Avoiding triggers like alcohol and hot beverages.
	- Smoking cessation.
- Obviously though, even though lifestyle modification is probably the most effective treatment, it’s tough to do.
- These all have strong evidence → Level 1C.</p>

<p><img class="right" src="/images/itdqugb3.png" /></p>

<p>####<strong>Non-Hormonal Treatment</strong>
- Many patients don’t want hormonal treatments.
- However, there are many non-hormonal treatments that are effective.
	- For vasomotor symptoms, anti-depressants, gabapentin, clonidine, and bellergal may be effective.
	- When you prescribe these to patients, tell them that it doesn’t mean that they have depression.
	- These can be considered when hormone therapy is contraindicated or not desired.
- A number of other non-hormonal options exist for the control of other symptoms.
	- Some of these are listed in the table to the right.</p>

<p><img src="/images/jsnnkj79.png" /></p>

<p>####<strong>Alternative Therapies</strong>
- <em>Limited evidence of benefit for most complementary and alternative approaches.</em>
	- Some, like St. John’s Wort, and Black Cohosh, have been shown to be statistically different from placebo.
	- Others have not.
- Advise with caution, since they may interfere with conventional treatment.
	- St. John’s Wort can interfere with antidepressents, and will reduce the effectiveness of warfarin, digoxin, and many other medications.
	- Black Cohosh can reduce the efficacy of estrogen replacement therapy.
- Most natural health products are not regulated under pharmaceutical regulations and are not rigorously tested.
- Lack evidence for safety and efficacy (IB).</p>

<p><img src="/images/sw3uzes_.png" /></p>

<p>####<strong>Hormone Replacement Therapy (HRT)</strong>
- “Healthcare providers should offer HRT as the most effective treatment for the medical management of menopausal symptoms” (IA)
- <strong>Either combined E+P, or E only in women without a uterus.</strong>
	- Estrogen improves vasomotor symptoms, sleep disturbances, sexual function, and mood.
	- <em>The progesterone taken with the estrogen is only used to protect against endometrial hyperplasia</em> (and possible cancer).
	- So if the women doesn’t have a uterus, this isn’t needed, so she can take estrogen only.
- OCP can be used in perimenopause for management of symptoms (IA)
- HRT can be taken in many different routes (orally, vaginaly, transdermally); the route of delivery should primarily be determined by patient preference.</p>

<blockquote>
  <p>####<strong>Contraindications to ERT and PRT</strong></p>

  <table>
    <thead>
      <tr>
        <th style="text-align: left">Estrogen Replacement Therapy</th>
        <th style="text-align: left">Progesterone Replacement Therapy</th>
      </tr>
    </thead>
    <tbody>
      <tr>
        <td style="text-align: left">Unexplained vaginal bleeding</td>
        <td style="text-align: left">Unexplained vaginal bleeding</td>
      </tr>
      <tr>
        <td style="text-align: left">Known or suspected carcinoma of the breast</td>
        <td style="text-align: left">Known or suspected carcinoma of the breast</td>
      </tr>
      <tr>
        <td style="text-align: left">Active thromboembolic disease</td>
        <td style="text-align: left">Pregnancy</td>
      </tr>
      <tr>
        <td style="text-align: left">Acute Liver Disease</td>
        <td style="text-align: left"> </td>
      </tr>
    </tbody>
  </table>
</blockquote>

<blockquote>
  <p>####<strong>Risks vs Benefits of HRT</strong></p>

  <table>
    <thead>
      <tr>
        <th style="text-align: left">Risks</th>
        <th style="text-align: left">Benefits</th>
      </tr>
    </thead>
    <tbody>
      <tr>
        <td style="text-align: left">Thromboembolic events (MI, strokes, etc.)</td>
        <td style="text-align: left">Decreased menopausal symptoms, improved QoL</td>
      </tr>
      <tr>
        <td style="text-align: left">Cardiovascular effects</td>
        <td style="text-align: left">Decreased osteoporosis/fracture risk</td>
      </tr>
      <tr>
        <td style="text-align: left">Breast cancer risk</td>
        <td style="text-align: left">Improved urogenital health</td>
      </tr>
      <tr>
        <td style="text-align: left">Endometrial hyperplasia, adenocarcinoma<br />(only if unopposed estrogen)</td>
        <td style="text-align: left">Decreased mortality</td>
      </tr>
      <tr>
        <td style="text-align: left"> </td>
        <td style="text-align: left">?Decreased Alzheimer’s (mixed)</td>
      </tr>
      <tr>
        <td style="text-align: left"> </td>
        <td style="text-align: left">?Decreased colon cancer (mixed)</td>
      </tr>
    </tbody>
  </table>
</blockquote>

<ul>
  <li><strong>Why is HRT so controversial?</strong>
    <ul>
      <li>In the past, we were using HRT as primary or secondary prevention of cardiovascular events.</li>
      <li>Observational studies suggested a benefit of ERT on cardiovascular health. However, no randomized controlled trials on this had been performed at that point.</li>
      <li>Later, <em>2 RCTs were performed that did not show a benefit.</em>
        <ol>
          <li><strong>HERs Trial</strong> (Heart and Estrogen/Progesterone Replacement Study)
            <ul>
              <li>This was the trial that looked at <em>secondary prevention</em>.</li>
              <li>There was no decrease in CAD over 4 years of treatment. In fact, there was an <i>increased risk</i> (RR 1.57) of a second event in the first year of use.</li>
              <li>Finally, it showed that there was a 3x increased risk of VTEs.</li>
            </ul>
          </li>
          <li><strong>WHI Trial</strong> (Women’s Health Initiative Study)
            <ul>
              <li>This was the trial that looked at <em>primary prevention</em>, in women given E+P or E only (if they had no uterus).</li>
              <li>Again, this saw an overall increase in CAD risk (RR 1.29) in the first year of use, for those using combined E+P.</li>
              <li>The E only arm didn’t show an increased risk, but it also didn’t show an increased benefit.</li>
            </ul>
          </li>
        </ol>
      </li>
      <li>After this, it became evident that <em>what we had been using as prevention for MIs was in fact a risk factor!</em></li>
      <li>Hence, HRT should be used in caution in women with a prior VTE or a stroke.
        <ul>
          <li>This isn’t an absolute contraindication, but a relative one.</li>
          <li>Risk is highest in the first year of Tx, and falls afterwards.</li>
        </ul>
      </li>
    </ul>
  </li>
</ul>

<blockquote>
  <p>####<strong>Objective</strong>
- <em>Identify HRT guidelines from the point of view of breast health</em>.</p>
</blockquote>

<ul>
  <li><em>“I need something for my hot flashes, but I have a history of breast cancer in my family, so I can’t be on HRT”</em>
    <ul>
      <li>This is a particularly hard topic to tackle, because <em>breast cancer has been associated with HRT.</em></li>
      <li>
        <ul>
          <li>A small increased risk has been seen in many trials with HRT use. However, there’s no increased risk if HRT is used for &lt;5 years, and it also seems to disappear within 5 years of stopping use.</li>
        </ul>
      </li>
      <li><em>In other words, there only seems to be an increased risk if you use HRT for over 5 years.</em></li>
      <li>It’s unclear whether this result is due to surveillance bias → are the women in the trial screened better for breast cancer?</li>
      <li>Note that breast cancer is the only cancer where there has been an association. If they have a FHx of any other cancers, there’s no associated risk.</li>
    </ul>
  </li>
  <li><em>Is the change in risk significant?</em>
    <ul>
      <li>Alcohol consumption of 2 drinks/day, and a lack of regular exercise are all more significant risk factors.</li>
      <li>In fact, the most significant risk factor for breast cancer identified is significant weight gain after menopause.</li>
      <li>So, although HRT is subject to a lot of controversy, it’s much more dangerous to be fat/lazy/drink.</li>
    </ul>
  </li>
</ul>

<p><img src="/images/ntt0oy6j.png" /></p>

<ul>
  <li><em>If a patient has risk factors for breast cancer, should they take HRT?</em>
    <ul>
      <li>With a first degree relative with breast cancer, woman’s risk increases 2-4 x.</li>
      <li>Adding HRT does not seem to <i>further increase</i> this risk according to multiple observational studies.</li>
      <li>However, there’s not enough data to establish safety in women with BRCA-1 or 2 mutations, or in women with prior breast cancer → it’s very difficult to recruit these women into trials, with all the controversy.</li>
      <li>In conclusion, it isn’t absolutely contraindicated, but most wouldn’t prescribe it in this situation.</li>
    </ul>
  </li>
</ul>

<blockquote>
  <p>####<strong>Objective</strong>
- <em>Construct a nutritional model for menopausal women including calorie recommendations to minimize weight gain, food groups and vitamins/minerals required, emphasis on heart and bone health</em>.</p>
</blockquote>

<ul>
  <li>Women find it harder to lose weight in the perimenopausal years, and during menopause.</li>
  <li>There is a change in metabolism and basal body fat percentages in menopausal women.</li>
  <li>Because of this, nutritional counselling is important.</li>
  <li><strong>From Canada’s Food Guide</strong>:
    <ul>
      <li>Diet rich in plant based food.</li>
      <li>Low saturated fat and trans-fatty acids.</li>
      <li>High in dietary fiber.</li>
      <li>6-8 glasses water per day.</li>
    </ul>
  </li>
  <li><strong>Diet and cardiovascular disease</strong>:
    <ul>
      <li>Fewer saturated and trans-fatty acids.</li>
      <li>Replace them with non-hydrogenated, and mono- and poly-unsaturated fats.</li>
      <li>Increase omega-3, flavenoids, folate, and soy intake.</li>
    </ul>
  </li>
  <li><strong>Diet and bone health</strong>:
    <ul>
      <li>Menopause results in reduced bone density, due to increased osteoclast activity.</li>
      <li>Diet alone is insufficient to prevent bone loss.</li>
      <li>Hence Calcium and Vitamin D supplementation is needed.</li>
      <li>SOGC guidelines → 1500 mg/d Calcium, 800 IU/d Vitamin D.</li>
      <li>Osteoporosis Canada recommends more Vitamin D (400-1000 IU in those &lt; 50; 800-2000 in those &gt; 50), and less calcium (1200 mg), compared to the SOGC guidelines.</li>
    </ul>
  </li>
</ul>

<blockquote>
  <p>####<strong>Objective</strong>
- Apply knowledge for risk reduction and treatment strategies for bone health in women entering menopause, women with risk factors for osteoporosis and women with risk of fracture</p>
</blockquote>

<ul>
  <li>See <a href="http://www.schulichnotes.com/endocrinology/2014/10/09/metabolic-bone-disease.html">Metabolic Bone Disease</a> from Endocrinology for review.</li>
  <li><em>Osteoporosis</em> → reduced quantity and quality of bone.</li>
  <li><strong>How do you assess osteoporosis risk?</strong>
    <ol>
      <li><em>Bone Mineral Densitometry (BMD)</em> → should be done in patients with 1 major, or 2 minor risk factors.
        <ul>
          <li>This looks at <i>current risk</i>.</li>
        </ul>
      </li>
      <li><em>Determine the 10 year risk of fracture</em>:
        <ul>
          <li>This looks at <i>future risk</i>.</li>
          <li>High → &gt;20%.</li>
          <li>Moderate → 10-20%.</li>
          <li>Low → &lt;10%.</li>
        </ul>
      </li>
    </ol>
  </li>
  <li><strong>When do you do a BMD scan?</strong>
    <ul>
      <li>See below:</li>
    </ul>
  </li>
</ul>

<p><img src="/images/py_pjqru.png" /></p>

<ul>
  <li><strong>How do you interpret BMD results?</strong>
    <ul>
      <li><em>Below 50, you look at the Z-score</em>.
        <ul>
          <li>Z-scores are calculated over the sample population of those within your age group.</li>
          <li><em>Z-score ≤ -2.0 is considered to be below the expected range</em> (ie. more than 2 standard deviations from the mean).</li>
        </ul>
      </li>
      <li><em>Above 50, you look at the T-score</em>.
        <ul>
          <li>T-scores compare your current bone density to what your estimated peak bone mass should have been.</li>
          <li><em>T-score ≤ -2.5 is considered osteoporosis.</em></li>
        </ul>
      </li>
    </ul>
  </li>
</ul>

<p><img src="/images/gw0p_09z.png" /></p>

<ul>
  <li><strong>How is this 10-year fracture risk identified?</strong>
    <ul>
      <li>As mentioned in the previous block, there are 2 fracture risk tools that have been validated in Canada → CAROC and FRAX.</li>
      <li>Choosing between the two depends on personal preference and convenience.
        <ul>
          <li><strong>CAROC</strong> → Joint Initiative of the Canadian Association of Radiologists and Osteoporosis Canada.</li>
          <li><strong>FRAX</strong> → Fracture Risk Assessment Tool, developed by the WHO.</li>
        </ul>
      </li>
      <li>CAROC stratifies your risk depending on your age, and your BMD result. It also modifies your risk depending on patient risk factors.</li>
      <li>CAROC is shown below:</li>
    </ul>
  </li>
</ul>

<p><img src="/images/bu-zuo19.png" /></p>

<ul>
  <li><strong>How should you treat patients with osteoporosis?</strong>
    <ul>
      <li><em>Treatment depends on the 10-year fracture risk.</em>
        <ul>
          <li><em>High risk</em> → pharmacologic therapy.</li>
          <li><em>Moderate risk</em> → treatment depends on the individual.</li>
          <li><em>Low risk</em> → preventative strategies (Ca, Vit D).</li>
        </ul>
      </li>
    </ul>
  </li>
  <li><strong>What pharmacologic therapies are available for high risk patients?</strong>
    <ul>
      <li>Again, see <a href="http://www.schulichnotes.com/endocrinology/2014/10/09/metabolic-bone-disease.html">Metabolic Bone Disease</a>.</li>
      <li><strong>Bisphosphonates</strong>
        <ul>
          <li><em>Alendronate, risedronate, Zoledronate</em>.</li>
          <li>Bind to calcium hydroxyapatite crystals at site of bone resorption where bone matrix is exposed.</li>
          <li>Lies inert in bone matrix until they’re released during bone resorption by osteoclasts.</li>
          <li>When they get released, they then cause deactivation and apoptosis of osteoclasts.</li>
          <li>Leads to a decrease in bone turnover and an increase in bone mineralization.</li>
          <li><em>Advantages</em> → well tolerated, easy to administer, proven effectiveness in RCTs, decrease vertebral and hip fractures.</li>
          <li><em>Disadvantages</em> → abdominal pain and dysphagia when taking it, hypocalcemia if inadequate Ca ingestion.
            <ul>
              <li>Rare (but dangerous) side effects include <em>osteonecrosis of the jaw</em> (ONJ), and <em>atypical femoral fractures</em>.</li>
            </ul>
          </li>
        </ul>
      </li>
      <li><strong>Denosumab</strong> 
        <ul>
          <li>Monoclonal antibody against RANK ligand.</li>
          <li>RANK ligand stimulates osteoclast activity. Recall that estrogen binds RANK-L, which is why bone density falls after menopause.</li>
          <li>Denosumab is given as a SQ injection once per 6 months.</li>
          <li>Decreases overall fracture rate of both vertebral, hip and non vertebral fractures.</li>
          <li><em>Advantages</em> → well tolerated, easy to administer, increased compliance, proved effectiveness in RCTs, decrease vertebral and hip fractures.</li>
          <li><em>Disadvantages</em> → hypocalcemia, HSK pain and hypersensitivity.
            <ul>
              <li>Also has the same rare risks as bisphosphones → osteonecrosis of the jaw and atypical femoral fractures.</li>
            </ul>
          </li>
        </ul>
      </li>
      <li><strong>Hormone Replacement Therapy</strong>
        <ul>
          <li>Estrogen acts as an antiresorptive by increasing osteoblast production of osteoprotegerin.</li>
          <li>This acts as an anti-osteoclast by binding to RANKL, inhibiting activity and resorption.</li>
          <li>In the past, people were excited about this; why not use osteoprotegerin as a treatment for osteoporosis?
            <ul>
              <li>However, it’s a very small peptide, that’s degraded very rapidly, so it has to be constantly infused.</li>
              <li>As a result, pharmaceutical companies aimed to develop an antibody that did the same thing → this is what resulted in the development of <em>Denosumab</em>.</li>
            </ul>
          </li>
        </ul>
      </li>
      <li><strong>SERMS</strong>
        <ul>
          <li><em>Raloxifene, tamoxifen</em>.</li>
          <li>Maximizes the beneficial effects of estrogen on bone while minimizing effects on breast and endometrium.		
            <ul>
              <li>
                <ul>
                  <li>Modest BMD increases at spine and hip</li>
                </ul>
              </li>
              <li>Decreases risk of vertebral fracture</li>
              <li>No change in risk of hip fractures seen in RCTs</li>
            </ul>
          </li>
          <li>So unlike HRT, this <em>doesn’t increase the risk of endometrial hyperplasia and breast cancer.</em></li>
          <li>Sadly, this still affects receptors in the vasculature, so <em>thromboembolic risks still exist</em>.</li>
          <li>It also doesn’t affect receptors in the brain, so it <em>doesn’t reduce vasomotor symptoms</em>.</li>
          <li><em>Advantages</em> → reduced vertebral fractures, decreased risk of breast cancer by 50%.</li>
          <li><em>Disadvantages</em> → leg cramps, vasomotor symptoms, VTE risk, no effect on risk of hip fracture.</li>
        </ul>
      </li>
      <li><strong>Teriparatide</strong> (recombinant PTH)
        <ul>
          <li>Helps build new bone.</li>
          <li><em>Advantages</em> → decreases vertebral and non-vertebral fracture risk, decreased back pain.</li>
          <li><em>Disadvantages</em> → nausea, headaches, hypercalcemia, $$$ ($1000/month).</li>
        </ul>
      </li>
    </ul>
  </li>
</ul>

<p><img src="/images/0b_gy2ix.png" /></p>

<blockquote>
  <p>####<strong>Summary of Pharmacologic Therapies for Osteoporosis</strong></p>

  <ul>
    <li><strong>Anti-resorptive Drugs</strong>:
      <ul>
        <li><em>Bisphosphonates</em> → osteoclast inhibitors.</li>
        <li><em>Denosumab</em> → monoclonal antibody against RANK ligand, inhibits osteoclasts.</li>
        <li><em>SERMs</em> → Selective Estrogen Receptor Modulators.</li>
        <li><em>HRTs</em>.</li>
      </ul>
    </li>
    <li><strong>Bone-building Drugs</strong>:
      <ul>
        <li><em>Teriparatide</em>.</li>
      </ul>
    </li>
    <li>Of the anti-resorptive drugs, <em>bisphosphonates</em> and <em>denosumab</em> are the most used. Teriparatide is the only drug that increases bone mass.</li>
  </ul>
</blockquote>

<p><img src="/images/r37zjl_i.png" /></p>
                
                </div>
            </div>
            <div class="pagination">
                <div style="width:50%; float:left;">
                     
                        <a class="newer" href="http://www.schulichnotes.com/reproduction/2014/11/24/clinical-exam-cervix.html"><i class="fa fa-angle-left"></i> Clinical Exam of the Cervix</a> 
                     
                </div>
                <div style="width:50%; float:right;">
                     
                        <a class="older" href="http://www.schulichnotes.com/reproduction/2014/11/25/pelvic-organ-prolapse.html">Pelvic Organ Prolapse <i class="fa fa-angle-right"></i></a> 
                     
                </div>
            </div>
        </div>
    </div>
    <script src="http://www.schulichnotes.com/reproduction/index.js" type="text/javascript"></script>
<link rel="stylesheet" href="/resources/stylesheets/search.css">	
<script src="/resources/libraries/tipuesearch_set.js" type="text/javascript"></script>
<script src="/resources/libraries/tipuesearch.js" type="text/javascript"></script>
<script src="/resources/libraries/classie.js" type="text/javascript"></script>
<script>
var search = document.getElementById('header-search-icon');
var searchbar = document.getElementById('header-search-bar');
search.onclick = function(){classie.toggle(searchbar, 'search-bar-open');}
$(document).ready(function() {$('#tipue_search_input').tipuesearch();});
</script>
</body>
</html>